Natalizumab Treatment in Multiple Sclerosis


Kurtuncu M.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.48, pp.56-60, 2011 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 48
  • Publication Date: 2011
  • Doi Number: 10.4274/npa.y6430
  • Title of Journal : NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
  • Page Numbers: pp.56-60

Abstract

Natalizumab is the first monoclonal antibody approved for the treatment of multiple sclerosis. It is an alpha 4-integrin antagonist that inhibits transmigration of peripheral lymphocytes through the blood-brain barrier. Natalizumab is recommended only for patients who continue to worsen under interferon or glatiramer acetate treatment or who do not tolerate those treatments. Since this drug might occasionally lead to opportunistic infections such as PML, clinicians should always consider the risk-benefit ratio when they decide to use this treatment. (Archives of Neuropsychiatry 2011:48 Supplement 2:56-60)